IP Library Granted Patent US 9,439,405
Granted Patent B2
US 9,439,405 · App. 13/654,007 · Granted Sep 13, 2016

Mouse λ light chain locus

Inventors: Marianne Brüggemann (Cambridge, GB); Xiangang Zou (Cambridge, GB)
Assignee: Crescendo Biologics Limited
A01K67/0276C07K16/00A01K2217/075A01K2227/105C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,405
App. No.
13/654,007
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention provides in a first aspect a mouse in which the λ (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse λ light chain locus was functional silenced by deletion of acne segments coding for the λ light chain locus. In a further aspect, a mouse containing functionally silenced λ and κ (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.

Claims (8)

1. A knock-out mouse having its mouse immunoglobulin lambda light chain locus deleted in part or completely through targeted integration and gene deletion or through gene deletion of segments encoding for the lambda light chain locus, wherein the complete or partial deletion of the mouse immunoglobulin lambda light chain locus consists of (1) a deletion of or targeted integration in lambda light chain gene C2 and a deletion of lambda light chain genes C3-C1; or (2) a deletion of lambda light chain genes C2, C4, C3 and C1.

2. A knock-out according to claim 1 , wherein the complete or partial deletion of the mouse immunoglobulin lambda light chain locus consists of a deletion of the lambda light chain genes C2, C4, C3 and C1.

3. A knock-out mouse according to claim 1 , wherein mouse has its lambda light chain locus deleted in part or completely through targeted integration using loxP constructs as targeting constructs.

4. A knock-out mouse according to claim 2 , wherein the lambda light chain genes C2, C4, C3 and C1 are deleted through targeted integration using loxP constructs as targeting constructs.

5. The knock-out mouse according to claim 1 , wherein the mouse immunoglobulin κ light chain locus is functionally silenced by targeted integration of a selectable marker gene in Cκ or targeted deletion of Cκ or Jκ.

6. The knock-out mouse according to claim 1 , wherein the mouse immunoglobulin heavy chain locus is functionally silenced by targeted integration of a selectable marker gene in the μ membrane exons or targeted deletion of the JH gene segments.

7. The knock-out mouse according to claim 1 , wherein the knock-out mouse comprises one or more heavy and/or a light chain immunoglobulin genes or loci from a human.

8. The knock-out mouse according to claim 5 , wherein the mouse immunoglobulin heavy chain locus is functionally silenced by targeted integration of a selectable marker gene in the μ membrane exons or targeted deletion of the JH gene segments.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: BRUGGEMANN, MARIANNE; ZOU, XIANGANG
To: THE BABRAHAM INSTITUTE
Reel/Frame 039292/0216 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: THE BABRAHAM INSTITUTE
To: TRANSLOCUS LIMITED
Reel/Frame 039292/0258 →
CHANGE OF NAME Recorded Jul 29, 2016
From: TRANSLOCUS LIMITED
To: CRESCENDO BIOLOGICS LIMITED
Reel/Frame 039292/0281 →
Priority Claims (1)
GB 0115256.0 · Jun 21, 2001 · national
Continuity (3)
Continuation 12476087 · Jun 1, 2009
Continuation 10481395
Related Publication 20130046079A1 · Feb 21, 2013